-
2
-
-
33846344076
-
-
Hadari, Yaron; Smith, Leon M., II. EGFR Tyrosine Kinase Inhibitors and Therapeutic Compositions Containing Them. WO 2005009384, 2005; 208 pp.
-
-
-
-
3
-
-
27644549570
-
-
Pan W., Liu H., Xu Y.-J., Chen X., Kim K., Milligan D., Columbus J., Hadari Y., Kussie P., Wong W., and Labelle M. Bioorg. Med. Chem. Lett. 15 (2005) 5474-5477
-
(2005)
Bioorg. Med. Chem. Lett.
, vol.15
, pp. 5474-5477
-
-
Pan, W.1
Liu, H.2
Xu, Y.-J.3
Chen, X.4
Kim, K.5
Milligan, D.6
Columbus, J.7
Hadari, Y.8
Kussie, P.9
Wong, W.10
Labelle, M.11
-
6
-
-
26244453587
-
-
Xu Y.-J., Liu H., Pan W., Chen X., Wong W., and Labelle M. Tetrahedron Lett. 46 (2005) 7523-7526
-
(2005)
Tetrahedron Lett.
, vol.46
, pp. 7523-7526
-
-
Xu, Y.-J.1
Liu, H.2
Pan, W.3
Chen, X.4
Wong, W.5
Labelle, M.6
-
7
-
-
27744581943
-
-
Duncton M., Smith II L., Burdzovic-Wizeman S., Burns A., Liu H., Mao Y., Wong W., and Kiselyov A. J. Org. Chem. 70 (2005) 9629-9631
-
(2005)
J. Org. Chem.
, vol.70
, pp. 9629-9631
-
-
Duncton, M.1
Smith II, L.2
Burdzovic-Wizeman, S.3
Burns, A.4
Liu, H.5
Mao, Y.6
Wong, W.7
Kiselyov, A.8
-
8
-
-
32044458119
-
-
Smith L., Piatnitski E., Kiselyov A., Ouyang X., Chen X., Burdzovic-Wizemann S., Xu Y., Wang Y., Rosler R., Patel S., Chiang H.-H., Milligan D., Columbus J., Wong W., Doody J., and Hadari Y. Bioorg. Med. Chem. Lett. 16 (2006) 1643-1646
-
(2006)
Bioorg. Med. Chem. Lett.
, vol.16
, pp. 1643-1646
-
-
Smith, L.1
Piatnitski, E.2
Kiselyov, A.3
Ouyang, X.4
Chen, X.5
Burdzovic-Wizemann, S.6
Xu, Y.7
Wang, Y.8
Rosler, R.9
Patel, S.10
Chiang, H.-H.11
Milligan, D.12
Columbus, J.13
Wong, W.14
Doody, J.15
Hadari, Y.16
-
9
-
-
33846371611
-
-
note
-
3): δ 160, 155.8, 154.8, 147.3, 130.8, 129.6, 128.7, 124.9, 123.3, 121.4, 49.6, 48, 26.3, 24.6.
-
-
-
-
10
-
-
33846340554
-
-
note
-
3): δ 157.3, 157.2, 148.8, 145.1, 137.4, 132.2, 129.2, 125.7, 122.4, 121.8, 115.1, 114.1, 114, 55.9, 47.5.
-
-
-
-
11
-
-
33846379701
-
-
note
-
All reactions were purified using HPLC-MS purification. Equipment: A Maccel semi-prep SH-C18 50 × 20 mm column was used. All compounds were purified using a Shimadzu HPLC system consisting of two LC-8A prep pumps, LC-10ADvp pump, 2 SPD-10A UV detectors, and an SCL-10A system controller. Two Gilson liquid handlers were used for injection and collection and a Waters ZQ mass spectrometer was used for detection. The Masslynx version 4.0 platform controlled the injections and tracked all data outputs. Experimental conditions: Purification was done by RP-HPLC with MS trigger using a gradient of water (solvent A) and acetonitrile (solvent B) with 0.1% TFA and a 2.5 min run time. Molecular weights were detected using positive electrospray ionization mode on the mass spectrometer with a cone voltage of 20 V. These conditions were optimized for individual compounds using varying acetonitrile/water gradients.
-
-
-
|